- |||||||||| Inlyta (axitinib) / Pfizer, vorolanib (EYP-1901) / EyePoint Pharma, Fumena (vorolanib) / Tyrogenex, Betta Pharma
Clinical, Journal: Vorolanib, sunitinib, and axitinib: A comparative study of vascular endothelial growth factor receptor inhibitors and their anti-angiogenic effects. (Pubmed Central) - Jun 4, 2024 Of the three TKIs, only axitinib potently inhibited TIE2 which is an undesired trait as TIE2 is essential for vascular stability. The findings support the use of vorolanib for therapeutic inhibition of angiogenesis observed in DR, DME, and wAMD.
- |||||||||| Iluvien (fluocinolone acetonide) / Alimera Sci, EyePoint Pharma
Journal, Real-world evidence, Real-world: The effectiveness of the 0.19 (Pubmed Central) - Jun 4, 2024 The findings support the use of vorolanib for therapeutic inhibition of angiogenesis observed in DR, DME, and wAMD. Our results suggest improvements and long-term maintenance in functional and anatomical outcomes with FAc implant with a manageable safety profile in a real-world clinical setting in patients with NIU-PS.
- |||||||||| Yutiq (fluocinolone acetonide intravitreal implant) / EyePoint Pharma, Iluvien (fluocinolone acetonide) / Alimera Sci, EyePoint Pharma
Review, Journal: Fluocinolone acetonide 0.2 (Pubmed Central) - May 30, 2024 As more clinical experience has been gained using FAc implants, it was necessary to update the clinical recommendations that guide patient management in the clinic. The current consensus document addresses relevant issues related to the use of FAc implants on different types of patients with various etiologies of NIU-PS, and was conducted to standardize approaches to help specialists obtain better clinical outcomes.
- |||||||||| Iluvien (fluocinolone acetonide) / Alimera Sci, EyePoint Pharma
Journal: Fluocinolone Acetonide Implant for Uveitis: Dissecting Responder and Non-Responder Outcomes at a Tertiary Center. (Pubmed Central) - May 25, 2024 The current consensus document addresses relevant issues related to the use of FAc implants on different types of patients with various etiologies of NIU-PS, and was conducted to standardize approaches to help specialists obtain better clinical outcomes. This study evaluated the efficacy of a fluocinolone acetonide (FAc) intravitreal implant (ILUVIEN
- |||||||||| Dexycu (dexamethasone intraocular injection) / EyePoint Pharma, Ocumension Therap
Trial completion date, Trial primary completion date, Surgery: A Study to Evaluate the Efficacy and Safety of DEXYCU (clinicaltrials.gov) - Apr 4, 2024 P3, N=0, Withdrawn, The Fluocinolone intravitreal implant may be an effective treatment for persistent CME in patients with immune recovery uveitis syndrome. Trial completion date: Apr 2024 --> Sep 2023 | Trial primary completion date: Apr 2024 --> Sep 2023
- |||||||||| Iluvien (fluocinolone acetonide) / Alimera Sci, EyePoint Pharma
Journal: Long-Term Control of Retinal Thickness Variability and Vision Following the 0.19 mg Fluocinolone Acetonide Implant. (Pubmed Central) - Nov 17, 2023 Purpose: To assess the impact of retinal thickness variability (RTV) control on visual and treatment burden outcomes in patients with diabetic macular edema (DME) who received the 0.19 mg fluocinolone acetonide (FAc) intravitreal implant (Iluvien, Alimera Sciences)...A multivariate linear regression with baseline BCVA as a covariate displayed improved correlations with the last-observed BCVA, CST-AUC (R?=?-0.448), RTA (R?=?-0.432), and RTSD (R?=?-0.436). The sustained corticosteroid release of the 0.19 mg FAc implant reduced RTV in patients with DME, which directly correlated with significantly improved vision and a reduced supplemental treatment burden.
- |||||||||| Yutiq (fluocinolone acetonide intravitreal implant) / EyePoint Pharma
Trial completion date, Trial primary completion date: Fluocinolone Acetonide Intravitreal Implant 0.18 mg in the Treatment of Chronic Non-Infectious Posterior Segment Uveitis (clinicaltrials.gov) - Oct 30, 2023 P4, N=125, Recruiting, The sustained corticosteroid release of the 0.19 mg FAc implant reduced RTV in patients with DME, which directly correlated with significantly improved vision and a reduced supplemental treatment burden. Trial completion date: Sep 2024 --> Nov 2025 | Trial primary completion date: Sep 2024 --> Nov 2025
- |||||||||| Ozurdex (dexamethasone intravitreal implant) / AbbVie, Xipere (triamcinolone acetonide) / Clearside Biomedical, Bausch Health, Arctic Vision, Yutiq (fluocinolone acetonide intravitreal implant) / EyePoint Pharma
Improvement of Postoperative Macular Edema Following Intravitreal Steroid Injections (POSTER THEATER) - Oct 28, 2023 - Abstract #AAO2023AAO_1661; CST and MV improved significantly at 6 weeks (?129 ?m, P ? 10-13; ?0.88 mm
- |||||||||| Iluvien (fluocinolone acetonide) / Alimera Sci, EyePoint Pharma
Journal, Real-world evidence, Real-world effectiveness, Real-world: Intravitreal fluocinolone acetonide 0.19 (Pubmed Central) - Sep 26, 2023 Although the rate of IOP-lowering medications use was higher than previously reported, the rate of incisional IOP-lowering surgery and other complications remained low and in keeping with rates reported in larger studies. The FAc implant is safe and effective at treating NIU over 12
- |||||||||| Yutiq (fluocinolone acetonide intravitreal implant) / EyePoint Pharma
Trial termination, Trial primary completion date: Safety and Efficacy of an Injectable Fluocinolone Acetonide Intravitreal Insert (FAI) (clinicaltrials.gov) - Sep 8, 2023 P3, N=12, Terminated, The FAc implant is safe and effective at treating NIU over 12 Active, not recruiting --> Terminated | Trial primary completion date: Apr 2023 --> Oct 2022; No longer pursuing indication
- |||||||||| Dexycu (dexamethasone intraocular injection) / EyePoint Pharma, Ocumension Therap
Enrollment change, Trial withdrawal, Surgery: A Study to Evaluate the Efficacy and Safety of DEXYCU (clinicaltrials.gov) - Sep 8, 2023 P3, N=0, Withdrawn, Active, not recruiting --> Terminated | Trial primary completion date: Apr 2023 --> Oct 2022; No longer pursuing indication N=150 --> 0 | Not yet recruiting --> Withdrawn
- |||||||||| Iluvien (fluocinolone acetonide) / Alimera Sci, EyePoint Pharma
Journal: Retinal changes after fluocinolone acetonide implant (ILUVIEN (Pubmed Central) - Jul 21, 2023 In persistent or recurrent DME, fluocinolone acetonide implantation can be effective in improving maculopathy stage and reducing the percentage of eyes with: intraretinal cysts; CFT?>?30% above the upper normal value; and disrupted or absent EZ and/or ELM. It can also increase BCVA and reduce CFT.
- |||||||||| Iluvien (fluocinolone acetonide) / Alimera Sci, EyePoint Pharma
Journal: Treatment of Iluvien (Pubmed Central) - Jun 19, 2023 It can also increase BCVA and reduce CFT. No abstract available
- |||||||||| Dextenza (dexamethasone punctal plug) / Ocular Therap, Dexycu (dexamethasone intraocular injection) / EyePoint Pharma, Ocumension Therap, Omidria (phenylephrine/ketorolac) / Omeros
Trial completion, Enrollment change, Surgery: Omidria and Dexycu, or Omidria and Dextenza Compared to Topical Prednisolone Acetate 1% Following Cataract Surgery (clinicaltrials.gov) - Jun 15, 2023 P4, N=15, Completed, No abstract available Unknown status --> Completed | N=75 --> 15
- |||||||||| Venclexta (venetoclax) / Roche, AbbVie, Xpovio (selinexor) / Karyopharm, Menarini, FORUS Therap
Enrollment open: SELVEDge: Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov) - Mar 30, 2023 P2, N=33, Recruiting, SC Iluvien is potentially effective in improving visual function, reducing macular edema, and reducing the incidence of steroid-induced cataracts and glaucoma. Not yet recruiting --> Recruiting
- |||||||||| Iluvien (fluocinolone acetonide) / Alimera Sci, EyePoint Pharma
Journal: Efficacy of 190 mcg fluocinolone acetonide intravitreal implant: microperimetry and OCT real-life data. (Pubmed Central) - Mar 24, 2023 According to the results of our study, fluocinolone acetonide (FAc) is a valid therapy option despite some limitations. It has been evidenced that FAc is more effective in patients with mild central macular thickening, while in those with modest to severe central macular thickness (CMT), different therapy strategies should be considered.
- |||||||||| vorolanib (EYP-1901) / EyePoint Pharma
Enrollment open: Study of EYP-1901 in Patients With Nonproliferative Diabetic Retinopathy (NPDR) (clinicaltrials.gov) - Feb 15, 2023 P2, N=105, Recruiting, It has been evidenced that FAc is more effective in patients with mild central macular thickening, while in those with modest to severe central macular thickness (CMT), different therapy strategies should be considered. Not yet recruiting --> Recruiting
- |||||||||| Review, Journal, Combination therapy: Therapeutic Effects of Combination Therapy and Photobiomodulation Therapy on Retinal Regeneration. (Pubmed Central) - Feb 7, 2023
We investigated the effects of various lasers photocoagulation such as Focal and/or grid macular laser, subthreshold micropulse laser (SMPL), as well as intravitreal pharmacotherapies with triamcinolone acetonide, and fluocinolone, and extended released intraocular implants such as Ozurdex, Retisert, Iluvien, and anti-vascular endothelial growth factors such as bevacizumab (Avastin), Eyela, and Lucentis...Therefore, combining the medication with a laser is much more reasonable than each alone. Also, the subthreshold photocoagulation laser (670 nm) is better at reducing the central macular thickness (CMT) and improving VA than the micro pulse yellow laser and pan-retinal photocoagulation (PRP).
- |||||||||| Yutiq (fluocinolone acetonide intravitreal implant) / EyePoint Pharma
Enrollment closed, Enrollment change, Trial primary completion date: Safety and Efficacy of an Injectable Fluocinolone Acetonide Intravitreal Insert (FAI) (clinicaltrials.gov) - Dec 21, 2022 P3, N=12, Active, not recruiting, EYP-1901 achieves sustained delivery of Vorolanib and a large phase 2 clinical trial is in development. Recruiting --> Active, not recruiting | N=60 --> 12 | Trial primary completion date: Oct 2022 --> Apr 2023
- |||||||||| Iluvien (fluocinolone acetonide) / Alimera Sci, EyePoint Pharma
Journal: Not quite an intraocular UFO: An IFO, "Iluvien floating object" (Pubmed Central) - Oct 4, 2022 The implant has been shown to be a safe option in the treatment of DMO and may have a role to play in achieving good functional and anatomical outcomes in DMO while also reducing the frequency of follow-up appointments required to maintain stable vision in the working-age population. No abstract available
- |||||||||| Venclexta (venetoclax) / Roche, AbbVie, Xpovio (selinexor) / Karyopharm, Menarini, FORUS Therap
New P2 trial: SELVEDge: Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov) - Sep 7, 2022 P2, N=33, Not yet recruiting,
|